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Background: Periocular melanoma is a rare but often deadly malignancy that arises 
in the uvea (commonest origin), conjunctiva or orbit (rarest primary site). Melanoma 
accounts for 5–10% of metastatic/secondary orbital malignancies, but only a tiny pro-
portion of primary orbital neoplasia. Primary orbital melanoma (POM) is exceedingly rare, 
with approximately 50 cases reported to date.
Methods: All patients seen in the orbital unit at a tertiary referral hospital (1991–2016) 
with a biopsy-proven diagnosis of POM were identified from a diagnostic database and 
were studied. The case notes, imaging, surgical approach, and histology were reviewed.
results: Thirteen patients (five male; 38%) presented with isolated malignant mela-
noma of the orbit, for which no other primary site was identified at presentation or 
during an average follow-up of 44 months (median 22; range 0–13 years). The patients 
presented between the ages of 40 and 84 years (mean 55.5; median 48 years) and 
typically gave a short history of rapidly increasing proptosis and eyelid swelling. On the 
basis of history, a malignant lesion was suspected in most patients and all underwent 
incisional biopsy, with debulking of the mass in 10 (77%) patients, and skin-sparing 
exenteration in 3/13 (23%). Ten patients underwent orbital radiotherapy and the survival 
to date ranged from 9 months to 14 years (mean 55 months; median 23 months); two 
patients received solely palliative care for widespread disease and one patient refused 
orbital radiotherapy. Five of the 13 (38%) patients died from the disease.
Discussion: POM is a very rare malignancy, but clinical analysis of this cohort gives 
insight into disease presentation and prognosis. The tumor typically presents with a rap-
idly progressive, well-defined mass that is, in some cases, amenable to macroscopically 
intact excision. Unusual for malignant melanoma, some of these patients can show an 
unusually long period of quiescent disease after surgical debulking and radiotherapy.
Keywords: primary orbital melanoma, orbital malignancy, ocular melanoma, melanoma, orbital surgery
inTrODUcTiOn
Periocular melanoma is a rare, generally lethal, malignancy that can arise from in the eye (uveal 
tract), the conjunctiva, or the ocular adnexa (eyelid or orbit) (1). Uveal origin—from the iris, ciliary 
body or choroid—is the commonest ocular melanoma, with conjunctival melanoma being the sec­
ond most frequent. The reported incidence of choroidal melanomas has increased in recent decades, 
TaBle 1 | Summary of published cases of primary melanoma within the orbit.
number 
of cases
gender age of  
onset
side Other features reference
1 M 34 L (15)
1 F 8 R Giant divided nevus (16)
1 F 34 L (17)
1 M 45 L Nevus of Ota (18)
1 M 60 L Poliosis (19)
1 M 50 R (20)
1 M 22 R (21)
1 F 64 R (22)
1 M 59 L (23)
1 F 43 R Blue nevus (24)
10 – Mean  
age = 57
– Survey of >1,200 
orbital neoplasia
(25)
1 F 36 R Episcleral nevus (26)
1 M 40 L (27)
3 F 45 Unknown Orbital nevus (28, 29)
F 33 Unknown Orbital nevus
M 43 R Orbital nevus
1 M 29 L Ocular melanosis (30)
1 F 49 L Ocular melanosis (31)
1 F 5 L (32)
21 – Mean  
age = 42
– Review of national 
pathology registry 
showed 19/21 had 
blue nevus
(33)
1 M 79 L (30)
1 M 76 R (34)
2 M 46 Unknown (35)
M 59 Unknown
1 F 17 R Ocular melanosis (36)
1 M 27 R Blue nevus (37)
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possibly because of greater exposure to UV light (2), or possibly 
due to greater detection. Eyelid melanomas are very rare, with 
knowledge limited to small case series (3–5).
Orbital melanoma occurs either as primary disease, as seco­
ndary disease (local invasion from a uveal, conjunctival, or eye­
lid primary tumor), or as metastatic disease from distant origins 
such as skin. Melanoma accounts for 5–20% of metastatic and 
secondary orbital malignancies, but only a minute proportion 
of primary orbital neoplasia (6–11). Primary orbital melanoma 
(POM) is extremely rare, with only about 50 cases reported to 
date (Table 1), and is thought to arise from melanocytic cells of 
the leptomeninges or ciliary nerves, or from ectopic intraorbital 
nests of melanocytes (12). POM can occur de novo, but it is 
often reported in association with pigmentary changes within 
periocular tissues—such as nevus of Ota, blue cellular nevus, 
or oculo­dermal melanosis; indeed, over a half of patients with 
nevus of Ota have pigmentation within the orbit, including 
oculo­dermal melanosis (13). While POM is reported to have a 
very poor prognosis, there have been sporadic reports of long­
survival, such as one patient who lived for almost 30 years after 
initial diagnosis (14).
Based on a series of patients with POM, this work aimed to 
extend the knowledge about clinical presentation, radiological 
appearance, surgical approach, and prognosis for this extremely 
rare condition.
PaTienTs anD MeThODs
All patients with a biopsy­proven diagnosis of POM, seen for 
diagnosis and treatment at Moorfields Eye Hospital between 
1991 and 2016, were identified from a clinical orbital diagnostic 
database and included in the study. The database comprised all 
patients seen by the orbital service at Moorfield’s Eye Hospital 
with a diagnosis of orbital malignancy, both primary and second­
ary. The histology slides were reviewed by an orbital malignancy­
expert pathologist, and where diagnostic uncertainty existed, a 
second opinion was sought by a melanoma­expert pathologist. 
The radiological imaging and clinical case notes were reviewed. 
Metastasis from a distant site was excluded by a thorough clinical, 
ultrasonographic, and (where available) histological examination 
of both uveal tracts, with a complete skin survey by consultant 
dermatologists at the patient’s local hospital, by review of systemic 
health during the follow­up interval, and by CT, MR, and, in some 
cases, PET imaging. This study received ethics approval from 
Moorfields Eye Hospital Biobank ethics board (15/SW/0104).
resUlTs
Thirteen patients (five men; 38%) with POM were identified, 
their mean age at presentation being 55.5  years (median 48; 
range 40–84 years) (Table 2). Twelve of the patients were white 
European, while one patient was West African (Table 2). The left 
orbit was more commonly affected (eight cases; 62%), and three 
patients had an underlying localized pigmentary abnormality 
(one nevus of Ota, one conjunctival nevus, one oculo­dermal 
melanosis).
clinical Presentation and imaging
All 13 patients presented with a history of unilateral proptosis 
with varying degrees of diplopia, and retro­orbital, or periorbital 
pain. The proptosis was generally rapidly progressive (over 
2–6  months), but in two cases, it had progressed slowly over 
4–5  years (patients 4 and 11; Table  2). Imaging consistently 
showed a relatively well­circumscribed, enhancing soft­tissue 
lesion that resembled benign lesions such as cavernous heman­
gioma (Figure 1).
Treatment
Diagnostic anterior orbitotomy and biopsy was done in all cases 
and a highly pigmented tumor was evident at surgery in ten 
cases (Figure 2A), and the other 3 patients (nos. 1, 7, and 13; 
Table 2) had lightly colored purple lesions. Well­defined lesions 
underwent macroscopically intact excision, whereas diffuse 
or infiltrative lesions had all visible tumor removed piecemeal 
(“debulked”). Primary orbital exenteration was not routinely 
performed for three reasons: first, primary debulking or intact 
excision effectively addresses the disease focus at initial surgery; 
secondly, there is no current evidence that exenteration— 
necessitating a second procedure—improves patient survival 
or reduces local disease recurrence; thirdly, our use of anterior 
orbitotomy (without disruption of bone or periosteum) still per­
mits future orbital exenteration if required for local progression 








































































































































































































































































































































































































































































































































































































































































































































































































































FigUre 1 | CT scan showing left orbital melanoma, with a typical 
configuration suggesting a well-defined benign mass; the rapid onset of 
symptoms over a few months, however, belies the sinister nature of the 
condition.
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cases and a fourth patient (Patient 4) underwent exenteration 
6 months after initial debulking, due to progression of the orbital 
disease. All patients were considered for adjuvant radiotherapy, 
but two patients (Cases 1 and 2) were too unwell to receive 
treatment, and Patient 4 declined it; the remaining nine patients 
received orbital radiotherapy at about 2–3 months after surgery, 
the standard protocol being 50–55 Gy in 200 cGy fractions over 
5 weeks. Of the 13 patients, nine individuals received primary 
treatment in the period before monoclonal antibody therapies 
became available for malignant melanoma. The four patients 
treated in recent years were genetically typed for likely response 
to monoclonal antibody therapy by standard methods in a 
diagnostic lab, and it was found that only one patient (patient 
13) was likely to benefit.
clinical course and Outcome
Eight of the thirteen patients are currently alive (at time of 
manuscript submission), with a mean survival of 44  months 
(median 22; range 9–175 months) and five have died from the 
disease—with highly variable survival between 3 and 174 months 
after diagnosis (mean 44; median 16 months) (Table 2).
Three patients had systemic involvement at presentation: 
Patients 1 and 2 had hepatic metastases and regional lymph node 
involvement, and both died within 4 months; patient 7 had tem­
poral lobe metastases at presentation and died 22 months later. 
Patient 8 developed a liver metastasis at 45 months, underwent 
partial hepatectomy, and remains in remission at 77  months 
after the primary orbital presentation. Patient 13 developed liver 
metastases at 5 months after orbital surgery and is currently being 
treated with monoclonal antibody therapy, with significant tumor 
regression.
Three patients had progressive or recurrent orbital disease, 
this being about 6 months after orbital diagnosis in two patients 
(Cases 5 and 8; Table 2). The third patient (Case 9) is known to 
have had diffuse and widespread orbital infiltration at primary 
4Rose et al. Primary Orbital Melanoma
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FigUre 2 | 47-year-old female presenting with primary malignant melanoma of the left orbit. (a) Melanoma (arrows) throughout orbital fat alongside the lateral 
rectus (on squint-hook) at time of incisional biopsy, and (B) CT scan of orbits prior to diagnostic biopsy, showing diffuse tumor infiltration of the left retrobulbar fat. 
(c) CT at 8 years after orbital radiotherapy, showing the inactive orbital disease that persisted for more than 13 years. (D) After 13 years there was a very rapid 
recurrence of tumor, from which the patient died about a year later.
surgery (Figures 2A,B), but remained with clinically and radio­
logically inactive orbital disease for 161  months (Figure  2C) 
before developing a rapidly progressive local recurrence that 
required multiple orbital tumor resections (Figure  2D); after 
inactive tumor for 13 years, the patient died with from dissemi­
nated malignancy within 13 months of orbital reactivation.
The eight currently alive patients have a wide variation in 
follow­up times (9–72  months), but the side­effect profile of 
debulking surgery with adjuvant radiotherapy appears to be 
good. There have been no complaints of serious post­operative 
pain or diplopia. Visual acuity has been affected in all individuals, 
but to varying extents, but some useful vision was retained in all 
patients after debulking surgery and radiotherapy.
DiscUssiOn
We present the clinical characteristics, treatment approaches, and 
long­term outcomes for 13 patients with POM, this representing 
the largest clinical series for this disease. Previous solitary case 
reports are consistent with our demographic findings—namely 
that most individuals are of white Northern European descent 
and present from the 5th decade (median age 48  years; range 
40–84). One patient was West African and this would appear to 
be unique. Review of previously published cases suggests onset at 
a mean age of 44 (median 42 years), with the youngest case occur­
ring in an 8­year­old girl and the oldest patient being 79 years 
(Table 1) (16, 38). Interestingly, two of our patients presented in 
their ninth decade, this being exceptionally late for POM. There 
does not appear to be any gender bias—with 19 affected men 
(14 previously reported + 5 in this study) and 18 affected women 
(10 previously reported + 8 in this study).
Imaging of patients consistently showed a well­circumscribed 
lesion that looked typically like a benign tumor or arteriovenous 
malformation; this characteristic has been previously described 
and might lead to delay in diagnosis and treatment of disease (39). 
MRI signal characteristics will generally help differentiate mela­
noma from benign lesions, such as cavernous hemangioma and 
could be considered in cases where there is diagnostic uncertainty 
(39). Our patients all had incisional biopsy and, where possible, 
resection of the mass, and all were considered for high­dose 
fractionated orbital radiotherapy to attempt control of residual 
local disease. Six patients underwent exenteration—three (Cases 
2, 4, and 6) to control disfiguring orbital disease, two (Cases 5 
and 8) for rapid disease progression after initial debulking, and 
one patient (Case 9) for very late recurrence of the orbital disease.
Despite reasonably uniform management, the outcome for 
this cohort of POM patients was highly variable: for example, 
two patients died very shortly after diagnosis, while three have 
survived 6 years or more. It would seem that this variable course 
does not depend solely on the presence of metastasis or systemic 
progression, as one of the longest surviving patients (Case 8) had 
partial hepatectomy for a liver metastasis. The surviving group 
(eight individuals, with three of these progressing to exentera­
tion) was insufficiently large to draw conclusions about long­term 
visual outcomes in this patient group. There have, however, been 
other larger studies of more common orbital malignancies treated 
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with a combination of surgery and radiotherapy that have shown 
good visual outcomes. For example, in a study of orbital rhab­
domyosarcoma, one third of patients maintained vision better 
than 6/9 in their treated eye, and approximately half maintaining 
vision of 6/9–6/60 (40).
Choroidal melanomas have been broadly classified as “type I” 
or “type II,” these following “aggressive” or “relatively indolent” 
courses, respectively. Several genetic signatures have been found 
for “type I” tumors—with monosomy 3, present in a half of uveal 
melanomas, being the most significant chromosomal aberra­
tion and strongly associated with metastasis and death (41, 42). 
Monosomy 3 affects prognosis due to tumor haploinsufficiency of 
BAP1—an important BRCA1­associated tumor suppressor gene 
(43, 44). Other chromosomal abnormalities, such as loss of 6q 
and gain of 8q, have been associated with poor prognosis in uveal 
melanoma (41). Point mutations in GNAQ and GNA11 have been 
identified in 80–90% of uveal melanomas and lead to activation 
of the MAPK/MEK/ERK pathway (43). It would be valuable to 
establish whether these genetic aberrations are present in POMs, 
and whether these relate to prognosis.
One patient (Case 9) is particularly interesting: despite receiv­
ing only orbital radiotherapy for widely infiltrating melanoma 
at the time of diagnosis (Figures 2A,B), she remained with no 
evidence of tumor proliferation until more than 13  years later. 
After tumor reactivation, however, it followed a very aggressive 
course (Figure 2C), requiring several palliative procedures, and 
the patient died 13  months later. Late metastatic or secondary 
melanoma to the orbit has been reported (45, 46), and similar 
genetic factors might possibly control the late recurrence of both 
primary and secondary orbital melanomas; alternatively, the 
orbital milieu might pre­dispose to a prolonged tumor latency 
before late recurrence.
In summary, POM is an extremely rare malignancy of rather 
variable prognosis after treatment, for which local resection with 
adjuvant radiotherapy remains the mainstay of therapy. Disease 
can remain quiescent for extended periods of time before follow­
ing an aggressive course. Immunotherapy might play a role in the 
future, but in this cohort, genetic testing did not suggest response 
to currently available agents in the majority of individuals. Further 
genetic investigation of these rare tumors might elucidate under­
lying molecular mechanisms of oncogenesis, thereby improving 
prognostication and treatment for this patient group.
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